Links, Resources & Stuff to Share with Your Hematologist
The Mysec Prognostic Model (MYSEC-PM)
Myelofibrosis on-line prognostic calculators
Additional Information and Support
Myelofibrosis Prognostic Scales, Journal Publications
Classification and Personalized Prognosis in Myeloproliferative Neoplasms — Grinfeld, J, Nangalia, J. et al. New England Journal of Medicine (2018)
MIPSS — Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project. Blood. 2014;124(21):405-405. bloodjournal.org/ content/124/21/405?sso-checked=true. https://www.hematologytimes.com/section/cythemias/article/team-develops-new-scoring-systems-for-pmf/
DIPSS — Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708. doi: 10.1182/blood-2009-09-245837.
DIPSS+ — Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–397. [PubMed]
GPSS — Tefferi A, Guglielmelli P, Finke C, et al. Integration of mutations and karyotype towards a Genetics-based Prognostic Scoring System (GPSS) for primary myelofibrosis. Blood. 2014;124(21):406-406. bloodjournal.org/ content/124/21/406.
Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013–1018. [PubMed]
IPSS — Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–2901. [PubMed]’
Grinfeld, et al., Personalized Prognostic Predictions for Patients with Myeloproliferative Neoplasms through Integration of Comprehensive Genomic and Clinical Information http://www.bloodjournal.org/content/130/Suppl_1/491
Passamonti, et al., Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)
More stuff to discuss with your hematologist
D. Arber, A. Orazi et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia (Fibrosis grade as independent variable.)